There are plenty of opportunities for investors if they follow us here at Insider Financial.
The key to trading stocks is finding the momentum BEFORE it happens and then be patient. Now, when we say that we find momentum BEFORE it happens, we are investors looking to position our subscribers BEFORE the move happens.
It’s also best to own a portfolio of penny stocks. For some that can be as many as 10 to 20 or more penny stocks that include both OTC stocks and NASDAQ penny stocks. In the present article, we’re about to discuss some hot stocks that can be part of your portfolio.
We alert our subscribers with our best ideas before our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here.
The fact is that there is always a bull market somewhere, even amid general bearishness. That’s why it’s important for hot stock investors to trade both OTC and NASDAQ stocks, and sometimes get exposure to larger companies that still seem to have massive growth potential. There are always opportunities if you give yourself the flexibility to trade all markets.
In this article, we take a look at 4 hot stocks to own, two of which are listed on NASDAQ. They are Goff Corp (OTCPK: GOFF), iSpecimen Inc (NASDAQ: ISPC), Longeveron Inc (NASDAQ: LGVN), and Tokens.com Corp (OTCPK: SMURF).
HOT STOCKS #1 GOFF
Goff Corp has been on the rise as it has obtained the Pink Current status ahead of schedule and is listed by brokers that support OTC stocks. The share price has surged by 170% this week and has tripled over the month to trade at $0.43, the highest in almost a decade. GOFF is now a $100 million company starting its journey and can update its ATH high within days or weeks.
GOFF said on Tuesday that the SEC had reviewed its Form 10 and had no questions, with the company becoming an SEC reporter.
The SEC has finished reviewing $GOFF's Form 10 and has no further questions. $GOFF is now officially an SEC reporter which should be reflected on OTC Markets soon (off the Expert Market) and then can be traded with all brokers.
— Worldwide NFT (@WorldwideNFTInc) November 23, 2021
GOFF has no operations at this point, but investors have high expectations given that it can be regarded as a blockchain play, as it’s currently seeking merger & acquisition candidates operating in what’s now the fastest-growing industry.
Investors are also interested in GOFF as it’s led by George A Sharp, a popular OTC scam investigator, consultant, and executive that is also active on social media. He has some great experience with blockchain firms especially thanks to his relationship with HUMBL, Inc (OTCPK: HMBL), which we covered on several occasions and which is seeking to uplist on OTCQB and then NASDAQ with Sharp’s support. Last year, when Sharp merged a shell with HMBL, the share price surged from less than three pennies to dollars. It eventually peaked at over $7 in February. Imagine how far GOFF can go.
GOFF could reach the $100 million market cap threshold being a shell – think about how far it can go when it announces and completes the blockchain merger. This is a big buy and a great OTC stock to hold.
— FisherTrades (@Fisher_Trades) November 26, 2021
HOT STOCKS #2 ISPC
Another $100+ million company making waves is iSpecimen Inc, but this one is listed on NASDAQ. The share price has jumped over 250% since last week to trade at $17.51 after peaking at over $24.
The company provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables researchers to browse through specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. ISPC operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The platform serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions.
ISPC is in a bullish mood after the company announced on Monday that it had been picked by the US government and private researchers to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments. In the last ten months, the company has partnered with multiple research and health care organizations on a range of diverse projects requiring a variety of COVID-19 samples, including nasal swabs, saliva, and blood products.
ISPC’s work on COVID-19 started right after the outbreak in 2020 when it began sending serum samples to the US Centers for Diseases Control and Prevention (CDC) to help researchers monitor antibody development for possible guidance on immunity. iSpecimen provided the CDC with 600 SARS-CoV-2-positive serum samples and 100 negative serum samples, mostly remnants from lab tests.
In addition, iSpecimen has been contracted by other federal agencies and private companies for custom COVID-19 collections, which are often complex and complement the more immediate availability of remnant or banked samples.
iSpecimen Founder and CEO, Christopher Ianelli, commented:
“COVID-19 has claimed more than 5 million lives, and it will require a lot of additional research to control the pandemic and improve society’s ability to contend with future outbreaks of infectious diseases. We embrace the challenge and are gratified that researchers are coming to us for the specific biospecimens they need from the types of patients they’re focusing on.”
Besides the collaboration with the CDC, iSpecimen has recently supplied hundreds of human biospecimens to ongoing COVID-19 research being conducted by the US military. The specimens, including positive SARS-CoV-2 samples and negative controls, help researchers validate COVID-19 testing platforms, understand fluctuations in patients’ antibody levels, monitor contagion among close contacts, and more.
All in all, ISPC is a good stock to hold as the markets struggle because of the new variant discovered in South Africa.
Earlier in November, the company released its financials, reporting that revenue increased 21% to $2.7 million for Q3 year-on-year, and was up 57% to $8.6 million for the first nine months of 2021. Recently, ISPC joined the Russell Microcap Index as part of the 2021 Russell indexes reconstitution.
HOT STOCKS #3 LGVN
Longeveron Inc is another NASDAQ-listed biotech stock surging in price, although it’s not a COVID play. The share price has increased by over 170% since the end of last week and almost 800% over the month, which is pretty impressive for a NASDAQ stock. What makes this move even more interesting is that LGVN tumbled to the lowest YTD last week at less than $3. The company went public earlier this year at $10, and on Wednesday, it hit a record high at over $42, with the market cap figure breaking above $600 million. Now the stock is trading at over $30 after a 28% correction since the recent high. In fact, if the bearish pressure continues, LGVN is about to become a good short squeeze candidate.
Longeveron is a clinical-stage biotechnology company that develops cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational product is the Lomecel-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, Alzheimer’s disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.
The price spike came after the company announced that the US Food and Drug Administration (FDA) had granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants.
Longeveron co-founder and Chief Science Officer Joshua M. Hare commented:
“We are encouraged by our Phase 1 clinical data, and the progress being made in the ongoing Phase 2 trial. Lomecel-B represents a unique cell therapy approach that could potentially be administered at the same time as surgery in these critically impacted infants.”
Approximately 1,000 babies are born with HLHS each year in the US HLHS babies have an underdeveloped left ventricle, which impairs the heart’s ability to pump blood throughout the body. HLHS is often fatal without surgical intervention, in which three surgical procedures are performed over the period of about 5 years, to allow the right ventricle to be configured to pump blood to the body. Longeveron is evaluating the safety of Lomecel-B injection into the right ventricle during the second surgery (4 – 6 months of age), and the effect on cardiac function and other health status endpoints.
Infants with HLHS are currently being enrolled in ELPIS II, a 38-subject, phase 2 randomized, double-blind, controlled clinical trial. ELPIS II is being funded in part by a grant from the National Institute of Health’s National Heart, Lung, and Blood Institute in collaboration with Longeveron, and is led by Principal Investigator Sunjay Kaushal, MD, Ph.D., Division Head, Cardiovascular-Thoracic Surgery, Ann and Robert H. Lurie Children’s Hospital of Chicago.
HOT STOCKS #4 SMURF
At the beginning of November, we presented the bullish case for Tokens.com, as the OTCQB stock leverages the Metaverse trend. The share price has more than doubled since then, currently trading at $2.75, after peaking at almost $3 on Friday to update the all-time high.
Tokens.com Corp is another blockchain play in today’s list, but it’s focusing on the Metaverse trend. The $210 million company provides transaction processing and validation services for various digital assets that power Decentralized Finance (DeFi) applications and Non-Fungible Token (NFT) platforms.
DeFi and NFTs have been the fastest-growing trends within the crypto space during the last year. The total value locked (TVL) in DeFi protocols is close to $105 billion, inches away from the recent record figure, as per DeFi Pulse data.
In October, Tokens.com announced that it had closed the acquisition of a 50% stake in Metaverse Group by issuing 2 million common shares at a price of CAD 0.84, making it one of the highest value equity investments ever in a specialized Metaverse real estate firm. It has increased its stake to 70% since then, becoming the parent company of Metaverse.
Metaverse Group is one of the world’s first virtual NFT based real estate companies and owns an extensive portfolio of virtual NFT real estate properties in major blockchain-based Metaverses, including Decentraland, Somnium Space, The Sandbox, Cryptovoxels, and Upland. Metaverse Group operates additional services, including virtual property development, property management, and assisting companies with marketing and advertising in the Metaverse.
A metaverse is a 3D online city where people can work, play games and communicate in a virtual environment. Tech firms have implemented metaverse elements in popular games, including Animal Crossing, Fortnite, and Roblox.
Besides Facebook, which plans to become a metaverse company, Microsoft has also embraced the metaverse as the convergence of the virtual and physical world which has only been accelerated with the pandemic.
At the end of November, SMURF announced the acquisition of a 116 parcel estate in the heart of the Fashion Street district within Decentraland via its new subsidiary. Decentraland has declared this to be the largest metaverse land acquisition to date. The estate will be developed to facilitate fashion shows and commerce within the exploding digital fashion industry. Speaking about Decentraland, its native cryptocurrency, MANA, updated the record high following the news to hit $5.5. MANA is now the 24th largest cryptocurrency on Coinmarketcap.
Meanwhile, SMURF is also building its Tokens.com Tower, which is a first-of-its-kind tower in Decentraland’s Crypto Valley. The tower is an NFT-based virtual building, under construction on Metaverse Group’s land parcels, of which Tokens.com owns 50%. The building is intended to be revenue-generating through leases, rentals and the sale of advertising space. Tokens.com Tower will be branded, providing Tokens.com and other brands advertising exposure to new audiences within the metaverse. Tokens.com will also use the space to host metaverse-based crypto conferences and events.
SMURF CEO Andrew Kiguel said:
“Within two years, all corporations and brands will require a metaverse strategy and presence. We are committed to being a central pillar in metaverse development and leading by example by establishing a presence in Decentraland. The Tokens.com Tower is meant to attract other top corporations and technology into Crypto Valley, which will drive innovation and help the region scale.”
We believe this is only the beginning for SMURF, which is poised to surge by leveraging the metaverse trend.
THE FINAL NOTE
Now is a great opportunity to invest in top penny stocks with great potential. Our job is to identify the best penny stocks with strong fundamentals and let our subscribers pick the ones they like to build a well-diversified portfolio.
Buying dips and selling rips as swing trades remains the best strategy in the stock market. Still, whenever a hot stock is in the middle of a bull run, we recommend our subscribers to book profits.
It’s very important to eye penny stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two penny stocks to run in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.